#Bosnia and Herzegovina - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 A poultry farm in Repuplika Srpska. 

Source: WOAH, https://wahis.woah.org/#/in-review/6258

_____

#Influenza A virus rapidly adapts #particle #shape to #environmental pressures

Abstract

Enveloped viruses such as influenza A virus (IAV) often produce a mixture of virion shapes, ranging from 100 nm spheres to micron-long filaments. Spherical virions use fewer resources, while filamentous virions resist cell-entry pressures such as antibodies. While shape changes are believed to require genetic adaptation, the mechanisms of how viral mutations alter shape remain unclear. Here we find that IAV dynamically adjusts its shape distribution in response to environmental pressures. We developed a quantitative flow virometry assay to measure the shape of viral particles under various infection conditions (such as multiplicity, replication inhibition and antibody treatment) while using different combinations of IAV strains and cell lines. We show that IAV rapidly tunes its shape distribution towards spheres under optimal conditions but favours filaments under attenuation. Our work demonstrates that this phenotypic flexibility allows IAV to rapidly respond to environmental pressures in a way that provides dynamic adaptation potential in changing surroundings.

Source: Nature Microbiology, https://www.nature.com/articles/s41564-025-01925-9

_____

#China reported two additional #human infection with avian #influenza virus A #H9N2 (HK CHP, Feb. 11 '25)

 {Excerpt}

Avian Influenza Report - VOLUME 21, NUMBER 6 - Reporting period: Feb 2, 2025 – Feb 8, 2025 (Week 6), (Published on February 11, 2025) 

-- Mainland China: 2 new cases (0 death cases): 

- Avian influenza A(H9N2): 

- Hunan Province: 

- 1) A two-year-old boy with onset on December 27, 2024.  

- 2) A 15-year-old boy with onset on January 8, 2025. 

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2025_avian_influenza_report_vol21_wk06.pdf

_____

#Coronavirus Disease Research #References (by AMEDEO, February 11 '25)

 

Ann Intern Med

1. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
   Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
   Ann Intern Med. 2025 Feb 4. doi: 10.7326/ANNALS-24-01015.
   PubMed         Abstract available
   
   

   
   Antiviral Res

2. UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al
   Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial.
   Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

3. SMITH EA, Javier GM, Multani A, Beaird OE, et al
   Anti-SARS-CoV-2 IgG Antibody Titers in Cotemporary lots of Intravenous Immune Globulin and Fresh Frozen Plasma Compared to COVID Convalescent Plasma.
   Clin Infect Dis. 2025 Feb 3:ciaf045. doi: 10.1093.
   PubMed         Abstract available
   
   
4. REGAN AK, Rowe SL, Sullivan SG, Coates MM, et al
   Coronavirus Disease 2019 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients.
   Clin Infect Dis. 2025 Feb 5:ciae580. doi: 10.1093.
   PubMed         Abstract available
   
   
5. MANDEL H, Yoo YJ, Allen AJ, Abedian S, et al
   Long-COVID incidence proportion in adults and children between 2020 and 2024.
   Clin Infect Dis. 2025 Feb 5:ciaf046. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

6. QUINT JK, Dube S, Carty L, Yokota R, et al
   Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.
   J Infect. 2025 Jan 29:106432. doi: 10.1016/j.jinf.2025.106432.
   PubMed         Abstract available
   
   

   
   J Med Virol

7. ZODDA E, Pons M, DeMoya-Valenzuela N, Calvo-Gonzalez C, et al
   Induction of the Inflammasome by the SARS-CoV-2 Accessory Protein ORF9b, Abrogated by Small-Molecule ORF9b Homodimerization Inhibitors.
   J Med Virol. 2025;97:e70145.
   PubMed         Abstract available
   
   
8. CHANG S, Shin J, Park S, Park H, et al
   Continuous Tracking for Effective Tackling: Ad5/35 Platform-Based JN1 Lineage Vaccines Development in Response to Evolving SARS-CoV-2 Variants.
   J Med Virol. 2025;97:e70206.
   PubMed         Abstract available
   
   
9. SUN J, Cheng J, Shi D, Xu X, et al
   Genetic Epidemiology of Porcine Epidemic Diarrhea Virus Circulating in China From 2010 to 2024: Characterization of Phylogenetic and Genetic Diversity of S1-Based Genes.
   J Med Virol. 2025;97:e70198.
   PubMed         Abstract available
   
   
10. PENG Y, Zhang Y, Zeng S, Cai C, et al
    A Comprehensive Pan-Cancer Analysis of COVID-19 Booster Vaccination Efficacy and Safety.
    J Med Virol. 2025;97:e70211.
    PubMed        
    
    

    
    J Virol

11. KUHN AJ, Outlaw VK, Marcink TC, Yu Z, et al
    Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.
    J Virol. 2025 Feb 4:e0215924. doi: 10.1128/jvi.02159.
    PubMed         Abstract available
    
    
12. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed         Abstract available
    
    
13. WANG X, Dong M, Wu X, Schnepf D, et al
    Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice.
    J Virol. 2025 Feb 4:e0141324. doi: 10.1128/jvi.01413.
    PubMed         Abstract available
    
    
14. PHAN T, Ribeiro RM, Edelstein GE, Boucau J, et al
    Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
    J Virol. 2025 Feb 4:e0162324. doi: 10.1128/jvi.01623.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

15. WANG Q, Mellis IA, Wu M, Bowen A, et al
    KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2.
    Lancet Infect Dis. 2025 Feb 4:S1473-3099(25)00058.
    PubMed        
    
    
16. SUTHAR MS, Manning KE, Ellis ML, Jain S, et al
    The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
    Lancet Infect Dis. 2025 Jan 31:S1473-3099(25)00007.
    PubMed        
    
    
17. XIE Y
    COVID-19 versus influenza: the need to align policies with COVID-19 realities.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(25)00001.
    PubMed        
    
    
18. BAGER P, Svalgaard IB, Lomholt FK, Emborg HD, et al
    The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022-24.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(24)00806.
    PubMed         Abstract available
    
    
19. LIU J, Yu Y, Yang S, Jian F, et al
    Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.
    Lancet Infect Dis. 2025 Jan 28:S1473-3099(25)00015.
    PubMed        
    
    

    
    Nature

20. LEDFORD H
    Four lessons COVID taught us about the immune system.
    Nature. 2025;638:19-20.
    PubMed        
    
    
21. LEE S, Yu Y, Trimpert J, Benthani F, et al
    Author Correction: Virus-induced senescence is a driver and therapeutic target in COVID-19.
    Nature. 2025 Feb 4. doi: 10.1038/s41586-025-08718.
    PubMed        
    
    
22. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron.
    Nature. 2025 Feb 5. doi: 10.1038/s41586-024-08511.
    PubMed         Abstract available
    
    

    
    Radiology

23. WEIR-MCCALL JR, Bell JS
    COVID-19 Infection and Coronary Plaque Progression: An Early Warning of a Potential Public Health Crisis.
    Radiology. 2025;314:e243767.
    PubMed        
    
    
24. DAI N, Tang X, Hu Y, Lu H, et al
    SARS-CoV-2 Infection Association with Atherosclerotic Plaque Progression at Coronary CT Angiography and Adverse Cardiovascular Events.
    Radiology. 2025;314:e240876.
    PubMed         Abstract available
    
    

    
    Science

25. GOSTIN LO, Meier BM
    A world less safe and secure.
    Science. 2025;387:559.
    PubMed         Abstract available
    
    

    
    Travel Med Infect Dis

26. PLAZA PI, Lambertucci SA
    Differences between Influenza H5N1, A/H1N1 2009, and SARS-CoV-2 in a pandemic risk scenario.
    Travel Med Infect Dis. 2025 Jan 31:102811. doi: 10.1016/j.tmaid.2025.102811.
    PubMed        
    
    

    
    Zhonghua Jie He He Hu Xi Za Zhi

27. WANG T, Chen X, Shi XP, He YX, et al
    [COVID-19 infection with tracheobronchomalacia: a case report].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:138-141.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, February 11 '25)

 

BMC Pediatr

1. KUDLACEK M, Fromel K, Groffik D, Mitas J, et al
   Individual physical activity preferences of adolescents in the Czech Republic and Poland: a 14-year comparative study reflecting the gender trends and prospective responses to global lifestyle challenges.
   BMC Pediatr. 2025;25:98.
   PubMed         Abstract available
   
   

   
   J Infect Dis

2. GOYA S, Wendm ST, Xie H, Nguyen TV, et al
   Genomic Epidemiology and Evolution of Rhinovirus in Western Washington State, 2021-2022.
   J Infect Dis. 2025;231:e154-e164.
   PubMed         Abstract available
   
   
3. CHIME N, Anspach B, Jain V, Laajalahti O, et al
   Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
   J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093.
   PubMed         Abstract available
   
   
4. BARZAGHI F, Visconti C, Pipitone GB, Bondesan S, et al
   Severe West Nile Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections in a Patient With Thymoma and Anti-Type I Interferon Antibodies.
   J Infect Dis. 2025;231:e206-e212.
   PubMed         Abstract available
   
   
5. NAIR MS, Luck MI, Huang Y, Sabo Y, et al
   Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro.
   J Infect Dis. 2025;231:e68-e76.
   PubMed         Abstract available
   
   
6. PISANIC N, Antar AAR, Hetrich MK, Demko ZO, et al
   Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution.
   J Infect Dis. 2025;231:121-130.
   PubMed         Abstract available
   
   
7. LIN LY, Gantner P, Li S, Su B, et al
   Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines.
   J Infect Dis. 2024 Sep 20:jiae464. doi: 10.1093.
   PubMed         Abstract available
   
   
8. BONOMO EJ, Shah M
   Rights-Based Legal Considerations for Tuberculosis Isolation Practices in Community Settings in the Postpandemic Era.
   J Infect Dis. 2025;231:31-36.
   PubMed         Abstract available
   
   
9. BUTT AA, Yan P, Abou-Samra AB, Shaikh OS, et al
   COVID-19 Disease Incidence and Severity in Previously Infected Unvaccinated Compared with Previously Uninfected Vaccinated Persons.
   J Infect Dis. 2024 Oct 8:jiae484. doi: 10.1093.
   PubMed         Abstract available
   
   
10. CHEW KW, McGinley B, Moser C, Li JZ, et al
    Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
    J Infect Dis. 2025;231:131-136.
    PubMed         Abstract available
    
    
11. BABU TM, Jackson LA, El Sahly HM
    Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration.
    J Infect Dis. 2024 Oct 16:jiae504. doi: 10.1093.
    PubMed         Abstract available
    
    
12. LORENZ N, James A, Van Rooyen T, Paterson A, et al
    Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic.
    J Infect Dis. 2025;231:e77-e81.
    PubMed         Abstract available
    
    
13. DESCALZO MA, de Paula Junior FJ, Mallegas NV, Penayo E, et al
    Annual estimation of seasonal influenza burden in six South American countries: a retrospective analysis of SARInet surveillance data to inform policies.
    J Infect Dis. 2025 Feb 1:jiaf037. doi: 10.1093.
    PubMed         Abstract available
    
    
14. JARA JH, Loayza S, Nogareda F, Couto P, et al
    Influenza vaccine averted illnesses in Chile, Guyana, and Paraguay during 2013-2018: a standardized approach to assess value of vaccination.
    J Infect Dis. 2025 Feb 1:jiaf038. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Neurosurg Pediatr

15. SALEH M, Lesha E, Nichols CS, Shimony N, et al
    A prospective observational study of operating room traffic during shunt surgery: who comes in and why?
    J Neurosurg Pediatr. 2024;35:167-173.
    PubMed         Abstract available
    
    

    
    J Virol

16. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
    Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
    J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
    PubMed         Abstract available
    
    

    
    Pediatrics

17. MUKHOPADHYAY S, Kaufman DA, Saha S, Puopolo KM, et al
    Late-Onset Sepsis Among Extremely Preterm Infants During the COVID-19 Pandemic.
    Pediatrics. 2025 Jan 23:e2024067675. doi: 10.1542/peds.2024-067675.
    PubMed         Abstract available
    
    
18. HE S, Esteban McCabe S, Conti RM, Volerman A, et al
    Prescription Stimulant Dispensing to US Children: 2017-2023.
    Pediatrics. 2025;155:e2024068558.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

19. LOMBARD B, Moultrie H, Pulliam JRC, van Schalkwyk C, et al
    Simulation-based validation of a method to detect changes in SARS-CoV-2 reinfection risk.
    PLoS Comput Biol. 2025;21:e1012792.
    PubMed         Abstract available
    
    

    
    PLoS Med

20. BHATIA A, Preiss AJ, Xiao X, Brannock MD, et al
    Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
    PLoS Med. 2025;22:e1004493.
    PubMed         Abstract available
    
    
21. RAGONNET R, Hughes AE, Shipman DS, Meehan MT, et al
    Estimating the impact of school closures on the COVID-19 dynamics in 74 countries: A modelling analysis.
    PLoS Med. 2025;22:e1004512.
    PubMed         Abstract available
    
    

    
    PLoS One

22. GOYAL A, Saeed H, Sultan W, Singh A, et al
    Mortality trends and disparities for coexisting chronic obstructive pulmonary disease and cardiovascular disease: A retrospective analysis of deaths in the United States from 1999-2020.
    PLoS One. 2025;20:e0317592.
    PubMed         Abstract available
    
    
23. BIBI N, Shah M, Khan S, Chohan MS, et al
    Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry.
    PLoS One. 2025;20:e0310855.
    PubMed         Abstract available
    
    
24. WARNER BM, Vendramelli R, Boese AS, Audet J, et al
    Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection.
    PLoS One. 2025;20:e0316952.
    PubMed         Abstract available
    
    
25. SCHUITEMA G, Lacchia A
    From anxiety to coping: Understanding psychological distance and coping skills for climate change and COVID-19 in 10-12-year-old children.
    PLoS One. 2025;20:e0317725.
    PubMed         Abstract available
    
    
26. SYKES BL, Chavez EK, Strong JD
    Death and disappearance: Measuring racial disparities in mortality and life expectancy among people in state prisons, United States 2000-2014.
    PLoS One. 2025;20:e0314197.
    PubMed         Abstract available
    
    
27. ZHANG C, Liu S, Qin M, Gao B, et al
    The dependency structure of international commodity and stock markets after the Russia-Ukraine war.
    PLoS One. 2025;20:e0316288.
    PubMed         Abstract available
    
    
28. FISCHER B, Farr M, Gummert J, Knabbe C, et al
    High-frequency PCR-testing as a powerful approach for SARS-CoV-2 surveillance in the field of critical infrastructure: A longitudinal, retrospective study in a German tertiary care hospital.
    PLoS One. 2025;20:e0317009.
    PubMed         Abstract available
    
    
29. COROCHER T, Edwards K, Hersusianto Y, Campbell D, et al
    Over-the-counter carrageenan-based sprays may interfere with PCR testing of nasopharyngeal swabs to detect SARS-CoV-2.
    PLoS One. 2025;20:e0316700.
    PubMed         Abstract available
    
    
30. ALUSTA P, Paredes A, Azevedo M, Mullis L, et al
    Direct detection and identification of viruses in saliva using a SpecID ionization modified mass spectrometer.
    PLoS One. 2025;20:e0316368.
    PubMed         Abstract available
    
    
31. KOSTIC K, Kostic A, Petrovic A, Vasilijevic A, et al
    The Serbian version of the Pandemic-Related Pregnancy Stress Scale (PREPS-SRB)-A validation study.
    PLoS One. 2025;20:e0317909.
    PubMed         Abstract available
    
    
32. SAFDARI A, Keshav CS, Mody D, Verma K, et al
    The external validity of machine learning-based prediction scores from hematological parameters of COVID-19: A study using hospital records from Brazil, Italy, and Western Europe.
    PLoS One. 2025;20:e0316467.
    PubMed         Abstract available
    
    
33. ARTOIS J, Vergne T, Fourtune L, Dellicour S, et al
    Spatial risk modelling of highly pathogenic avian influenza in France: Fattening duck farm activity matters.
    PLoS One. 2025;20:e0316248.
    PubMed         Abstract available
    
    
34. FUNK M, Reinke M, Lowe B, Engelmann P, et al
    Development of an expectation management intervention for patients with Long COVID: A focus group study with affected patients.
    PLoS One. 2025;20:e0317905.
    PubMed         Abstract available
    
    
35. SPITERI S, Salamon I, Girolamini L, Pascale MR, et al
    Surfaces environmental monitoring of SARS-CoV-2: Loop mediated isothermal amplification (LAMP) and droplet digital PCR (ddPCR) in comparison with standard Reverse-Transcription quantitative polymerase chain reaction (RT-qPCR) techniques.
    PLoS One. 2025;20:e0317228.
    PubMed         Abstract available
    
    
36. GANDJOUR A
    Health-economic evaluation of the outpatient, inpatient, and public health sector in Germany: Insights from the first three COVID-19 waves.
    PLoS One. 2025;20:e0314164.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

37. LIAO Y, Ma H, Wang Z, Wang S, et al
    Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.
    Proc Natl Acad Sci U S A. 2025;122:e2406659122.
    PubMed         Abstract available
    
    

    
    Vaccine

38. HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
    A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
    Vaccine. 2025;49:126780.
    PubMed         Abstract available
    
    
39. GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
    Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
    Vaccine. 2025;49:126802.
    PubMed         Abstract available
    
    
40. POWELL A, Jones A, Van Hout MC, Montgomery C, et al
    Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
    Vaccine. 2025;50:126837.
    PubMed         Abstract available
    
    
41. SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
    A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
    Vaccine. 2025;50:126847.
    PubMed         Abstract available
    
    

    
    Virology

42. POPOVIC ME, Tadic V, Popovic M
    (R)evolution of Viruses: Introduction to biothermodynamics of viruses.
    Virology. 2025;603:110319.
    PubMed         Abstract available
    
    
43. YANG S, Yang X, Zhu W, Luo C, et al
    The novel COVID-19 treatment VV116 is a potential inhibitor of Zika virus.
    Virology. 2024;603:110334.
    PubMed         Abstract available
    
    
44. ROY K, Saikia BK, Konwar R
    Exploring the role of carbon quantum dots as countermeasure for SARS-CoV-2 virus.
    Virology. 2025;603:110339.
    PubMed         Abstract available
    
    
45. JONES LR
    Intra-host variability of SARS-CoV-2: Patterns, causes and impact on COVID-19.
    Virology. 2025;603:110366.
    PubMed         Abstract available
    
    
46. CALDERON-PEREZ B, Nunez-Munoz LA, Trejo-Ayala LL, Rosales-Garcia VH, et al
    Immunogenicity of a multivalent protein subunit vaccine based on non-glycosylated RBD antigens of SARS-cov-2 and its variants.
    Virology. 2024;603:110380.
    PubMed         Abstract available
    
    
47. ZHAO Y, Li W, Xu L, Tao Z, et al
    Antibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
    Virology. 2025;603:110404.
    PubMed         Abstract available
    
    
48. MILLER JL, Niewiesk S
    Review of impaired immune parameters in RSV infections in the elderly.
    Virology. 2025;603:110395.
    PubMed         Abstract available
    
    
49. ZHIRNOV OP, Chernyshova AI
    The uncleaved viral hemagglutinin HA0 increases influenza A virus resistance to thermal pasteurization.
    Virology. 2025;604:110389.
    PubMed         Abstract available
    
    

    
    Virus Res

50. CHA RM, Park MJ, Baek YG, Lee YN, et al
    Genetic characteristics and pathogenesis of clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus isolated from poultry in South Korea, 2022-2023.
    Virus Res. 2025 Jan 31:199541. doi: 10.1016/j.virusres.2025.199541.
    PubMed         Abstract available

#Australia - High pathogenicity avian #influenza #H7N8 viruses (#poultry) (Inf. with) - Immediate notification

This is a confirmed case of H7N8 HPAI in a free-range commercial egg layer poultry farm. H7N8 virus is genetically related to strains detected in wild birds in Australia but different from the strains detected and eradicated in Australia in 2024. Biosecurity controls (quarantine) have been implemented on the farm. A detailed surveillance plan is being developed and epidemiological investigation and tracing is underway. Operational activities have commenced immediately. A Control Area (CA) and Restricted Area (RA) have been declared around the premises. Movement controls are being implemented in the CA and RA. A public information strategy has been employed. All coordinates provided are approximate to the nearest town location. Outbreak location: Victoria State.

Source: WOAH, https://wahis.woah.org/#/in-review/6249

_____

#Ukraine - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

Unspecified species of domestic birds in Sumy Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6251

_____

#UK - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 Two Greylag Goose, one Eurasian buzzard, two Eurasian Jackdaw, one Whooper Swan, one Common Guineafowl in Northern Ireland.

Source: WOAH, https://wahis.woah.org/#/in-review/6248

_____

#USA, Confirmed #human #H5N1 #influenza virus case #summary since 2024, by state and exposure source: One new case in #Nevada (Feb. 10 '25)

{Excerpt}

[State - Exposure Source: Exposure Associated with Commercial Agriculture and Related Operations: Dairy Herds (Cattle) - Poultry Farms and Culling Operations - Other Animal Exposure† - Exposure Source Unknown‡ - State Total]

1) California - 36 - 0 - 0 - 2 - 38

2) Colorado - 1 - 9 - 0 - 0 - 10

3) Iowa - 0 - 1 - 0 - 0 - 1

4) Louisiana - 0 - 0 - 1 - 0 - 1

5) Michigan - 2 - 0 - 0 - 0 - 2

6) Missouri - 0 - 0 - 0 - 1 - 1

7) Nevada - 1 - 0 - 0 - 0 - 1 {+1}

8) Oregon - 0 - 1 - 0 - 0 - 1

9) Texas - 1 - 0 - 0 - 0 - 1

10) Washington - 0 - 11 - 0 - 0 - 11

11) Wisconsin - 0 - 1 - 0 - 0 - 1

-- Source Total - 41 - 23 - 1 - 3 - 68 {+1}

NOTE: One additional case was previously detected in a poultry worker in Colorado in 2022. Louisiana reported the first H5 bird flu death in the U.S.

{†} Exposure was related to other animals such as backyard flocks, wild birds, or other mammals

{‡} Exposure source was not able to be identified

Probable human case summary during the 2024 outbreak, by state and exposure source

When a case tests positive for H5 at a public health laboratory but testing at CDC is not able to confirm H5 infection, per Council of State and Territorial Epidemiologists (CSTE) guidance, a case is reported as probable.

-- Probable cases with commercial poultry exposure (e.g., poultry farms or culling operations):

1) Washington (3)

2) Arizona (2)

-- Probable cases with commercial dairy (cattle) exposure:

1) California (1)

-- Probable cases with exposure source unknown:

1) Delaware (1)

Confirmed and probable cases are typically updated by 5 PM EST on Mondays (for cases confirmed by CDC on Friday, Saturday, or Sunday), Wednesdays (for cases confirmed by CDC on Monday or Tuesday), and Fridays (for cases confirmed by CDC on Wednesday and Thursday). Affected states may report cases more frequently.

(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/situation-summary/?CDC_AAref_Val=https://www.cdc.gov/flu/avianflu/avian-flu-summary.htm

_____

Novel #H16N3 avian #influenza viruses isolated from migratory #gulls in #China in 2023

Abstract

As a rare subtype of avian influenza virus, H16 viruses are predominant in gulls but rarely found in domestic birds. The low prevalence of H16 viruses has limited our understanding of their epidemiology and evolutionary dynamics. In this study, we isolated three novel H16N3 viruses from migratory gulls in East Asian–Australasian Flyway in eastern China in 2023, which are significantly different from previously identified isolates. To fully understand the epidemiology and genetics characteristics of the global H16 viruses, we compared the host divergence of several rare subtypes and determined that the H13 and H16 subtypes were predominantly pooled into different species of gulls by sharing their internal genes, whereas the waterfowl of Anatidae served as the primary natural reservoirs of the H8, H11, H12, H14, and H15 subtypes. Detailed phylogenetic analysis revealed the evolutionary divergence of globally circulating H16 viruses and their frequent gene reassortment. Furthermore, the gull origin H13 and H16 viruses collectively served as gene donors for the newly emerged highly pathogenic clade 2.3.4.4b H5N1 viruses because the H13/H16-like PA, NP, and NS genes have been introduced into circulating H5N1 viruses since May 2022 in Europe. To date, the H5N1 reassortants containing the H13/H16-like gene segments have been detected in wild and domestic birds and resulted in mammal and human infections. These results improve our knowledge of the ecology and genetics of H16 viruses and emphasize the need for surveillance to monitor the emergence of novel avian influenza viruses in migratory birds.

Source: Frontiers in Microbiology, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1543338/full

_____

Reduction of #Influenza A Virus #Prevalence in #Pigs at Weaning After Using Custom-Made Influenza #Vaccines in the Breeding #Herds of an Integrated Swine #Farm System

Abstract

Vaccination is a common influenza A virus (IAV) control strategy for pigs. Vaccine efficacy depends on strain cross-protection and effective vaccination program implementation. We evaluated a multi-faceted IAV vaccination strategy which included (a) monthly surveillance of pigs at weaning, (b) selection of epidemiologically relevant strains from farms under surveillance, (c) updating IAV strains in custom-made vaccines, and (d) seasonal mass vaccination with custom-made vaccines given to sows in 35 farrow-to-wean farms within an integrated swine farm system. Reduction of IAV in pigs from vaccinated sows was determined by monthly monitoring of farms for 30 months by IAV rRT-PCR (PCR) testing of nasal wipes collected from litters of piglets at weaning. Hemagglutinin (HA) nucleotide and amino acid (AA) sequence homology of the circulating and vaccine strains was determined by pairwise alignment and AA comparison at antigenic sites. Of the 35 farms monitored, 28 (80%) tested positive at least once, and 481 (5.75%) of 8352 PCR tests were IAV positive. Complete HA sequences were obtained from 54 H1 (22 H1-δ_1B.2.1, 28 H1-γ_1A.3.3.3, and 4 H1-pdm_1A.3.3.2 clades) and 14 H3 (12 IV-A 3.1990.4.1 and 2 IV-B 3.1990.4.2 clades) circulating IAV strains. During the study, custom-made vaccines were updated three times (eight strains total) and administered to sows at five distinct time periods. The HA AA similarity between vaccine and circulating strains ranged from 95% to 99%; however, the 0 to 71% similarity at HA antigenic sites prompted the vaccine updates. Herd IAV prevalence decreased from 40% (14/35) to 2.9% (1/35), accompanied by a numerical reduction in IAV-positive samples post-vaccination. Our results support having a comprehensive approach to controlling influenza in swine herds that includes surveillance, vaccination, and careful program implementation to reduce IAV in pigs.

Source: Viruses, https://www.mdpi.com/1999-4915/17/2/240

_____

South #Sudan declares #mpox #outbreak

Juba, 7 February 2025—Today the Ministry of Health has declared a mpox outbreak in Juba, Central Equatoria State. This declaration follows a confirmation mpox Case by the National Public Health Laboratory on 6 February 2025.

“The first case was reported on 6 February 2025 at Gudele Hospital from a Ugandan national and a resident of Kupuri Camp in Juba. The confirmed case is under isolation and is being managed at Gudele Hospital”, said the Acting Health Minister, Honorable James Hoth Mai, in a press conference in Juba. 

A team of experts from national and subnational levels, WHO, and other partners have been mobilized to conduct a detailed field investigation, list all contacts, and ensure close follow-up, Hon. Mai added.

He also added that the Ministry of Health and WHO have taken steps to manage the reported case properly, ensuring that every contact on the ground is followed. He assured the citizens not to panic but to stay calm and follow safety measures that the government is committed to stopping the spread of mpox in South Sudan.

Addressing the press conference, Dr Humphrey Karamagi, WHO Country  Representative in South Sudan, commended the Ministry of Health for declaring the outbreak. 

The announcement enables the public to take prevention measures, helps health partners take the necessary steps to contain the outbreak, and unlocks the required resources for fighting the outbreak. 

The confirmation of mpox in South Sudan showcases the national capabilities that WHO is proud to have significantly supported, said Dr Karamagi.

With this outbreak, South Sudan becomes the 22nd country to be affected in the African region. After this confirmation, my team will support the referral of the positive sample to WHO-collaborating laboratories for sequencing and genetic characterization of the Mpox virus detected in the country.

Dr Karamagi further reiterated WHO’s commitment to assisting the South Sudanese government and partners in enhancing disease surveillance, improving response coordination, and ensuring the availability of supplies. This includes supporting case management, laboratory testing, sample collection, transportation, and follow-up.

“Thanks to funding from our donors, WHO deployed experts and provided technical and logistical support,” said Dr Karamagi.

With the support of WHO, the Ministry has activated the Public Health Emergency Operations Center and prepared to coordinate responses to Mpox outbreaks, following the WHO guidelines. 

An Incident Manager and key health officials have been assigned to monitor five main entry points into South Sudan for suspected Mpox cases from high-risk neighboring countries like the Democratic Republic of the Congo (DRC), Uganda, and Kenya. 

All healthcare providers, including those in private practice, are receiving training on recognizing and responding to Mpox symptoms. We are developing a laboratory network and have tested samples from 141 suspected cases. 

New testing methods have been implemented, guaranteeing accurate results via external quality checks. 

Recent tests showed a 100% success rate, and our laboratory excelled in proficiency assessments. Moreover, 40 clinicians have received training in Mpox case management to ensure effective treatment and bolster our readiness for any possible Mpox outbreaks in South Sudan.

The Hon. Minister also urged the communities to practice good and safe behaviors, such as avoiding close contact with an infected person, using personal protective equipment when caring for patients, not sharing bedding, clothing, towels, or utensils with sick people, practicing hand hygiene and respiratory etiquette, isolate infected patients, avoid contact with wild animals and cook all food containing fresh animal meat before eating.

He urged health workers to remain vigilant with high index suspicious for mpox, adhere to infection prevention and control measures, follow standard operating procedures, and report suspected cases for further investigation. 

The press conference was attended by the media, high-level government officials, and partners, among others.

Source: World Health Organization, Regional Office for Africa, https://www.afro.who.int/countries/south-sudan/news/south-sudan-declares-mpox-outbreak

_____

Christ and the Woman taken in Adultery, Pieter Bruegel the Elder (c.1565)

 Public Domain.

Source: WikiArt, https://www.wikiart.org/en/pieter-bruegel-the-elder/christ-and-the-woman-taken-in-adultery-1565-1

_____

Limited #transmission of avian #influenza viruses, #avulaviruses, #coronaviruses and #Chlamydia sp. at the interface between wild #birds and a free-range duck #farm

Abstract

Recent outbreaks of highly pathogenic avian influenza in Europe have raised questions regarding the epidemiological role of commensal wild birds on free-range poultry farms. This study aimed to assess the prevalence of avian influenza viruses (AIV), avulaviruses, coronaviruses and Chlamydia sp. in commensal wild birds on a free-range duck farm in southwestern France and to evaluate possible transmission events at the wild‒domestic interface. From 2019 through 2021, a longitudinal study was conducted on wild birds, domestic ducks and their shared environment on farms. Commensal wild birds were captured and sampled for blood and swabs, and fresh feces from cattle egrets visiting the farm were collected. In parallel, domestic ducks were sampled, and environmental samples were collected. The presence of the four pathogens was tested by q(RT-)PCR, and the immunity of wild birds to AIV and Newcastle disease virus (NDV) was tested by ELISA. Wild birds were found to shed AIV and Chlamydia only, with a low prevalence (< 3%). The seroprevalence rates were less than 10% for AIV and less than 4.5% for NDV. No significant temporal trend was identified. Ducks and their environment frequently test simultaneously positive for the same pathogens (19 to 44% of flocks), mostly during fall‒winter. In addition to unrelated temporal patterns, the identification of pathogens in wild birds seemed unrelated to that in domestic ducks. These results suggest a low transmissibility of the avian pathogens tested in our study at the wild‒domestic interface and highlight the limited contribution of commensal wild birds in comparison with free-range poultry to the global microbiological pressure on the environment.

Source: Veterinary Research, https://veterinaryresearch.biomedcentral.com/articles/10.1186/s13567-025-01466-3

_____

#Pathology of #Influenza A (#H5N1) #infection in #pinnipeds reveals novel tissue #tropism and vertical #transmission.

Abstract

In 2023, an unprecedented outbreak of highly pathogenic avian influenza (HPAI) H5N1 resulted in the death of thousands of pinnipeds along the Argentinean coast, raising concerns about its ecological and epidemiological impact. Here, we present clinical, pathological, and molecular findings associated with HPAI H5N1 infection in pinnipeds from Chubut, Argentina. Necropsies were conducted on three South American Sea Lions (SASLs) (Otaria flavescens) and one Southern Elephant Seal (SES) (Mirounga leonina), followed by histopathological, immunohistochemical and RT-sqPCR analyses. Neurological clinical signs were observed in two SASLs, with one also exhibiting respiratory distress. Neuropathological findings included lymphoneutrophilic meningoencephalomyelitis and choroiditis, neuronal necrosis, gliosis, hemorrhages, and perivascular cuffing. Viral antigen was localized in neurons, glial cells, choroid plexus epithelial cells, ependymal cells, and the neuropil. Systemic manifestations included HPAI-related necrotizing myocarditis in the elephant seal and placental necrosis in a sea lion, with fetal tissues testing positive for HPAIV. Pulmonary lesions were minimal, limited to bronchial glands in one individual. RT-sqPCR confirmed HPAI H5 in all tested animals. Our findings highlight the neurotropism of HPAI H5N1 in pinnipeds, and expand the known systemic effects of the virus, revealing new tissue tropism and vertical transmission.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.02.07.636856v1

_____

{#USA, #Nevada} The Occurrence of Another Highly Pathogenic Avian #Influenza (HPAI) #Spillover from Wild #Birds into Dairy #Cattle

Background  

In March 2024, the USDA confirmed the first case of highly pathogenic avian influenza (HPAI) spreading between dairy cattle herds in the United States. 

This followed reports from dairy producers of an unusual illness in their lactating cows over the preceding 2-3 months. 

Virus whole genome sequencing and modeling performed by USDA suggested a single spillover of HPAI H5N1, clade 2.3.4.4b, genotype B3.13 from wild birds into dairy cattle likely occurred between October 2023 and January 2024 (1). 

Since then, federal, state, and industry partners have collaborated to address the HPAI threat in dairy cattle, resulting in two federal orders and the implementation of the National Milk Testing Strategy (NMTS). 

States began enrolling in the NMTS in December 2024, in which they are continuing to conduct or now implementing state-wide bulk tank surveillance and/or milk processing plant silo monitoring. 

Nevada was among the first to participate in the National Silo Monitoring Program, which includes testing milk samples from processing plant silos for HPAI. 

This sampling scheme coincides with the FDA's existing regulatory program, which requires all raw milk Grade A silos to be sampled four times within 6 months. 

The Detection In Nevada, 3 of 11 silo samples collected on January 6 and 7, 2025 tested positive for HPAI via polymerase chain reaction (PCR) at the National Veterinary Services Laboratories (NVSL) on January 10. 

The state was notified, triggering an investigation to trace the source, as up to  12 dairies (in the same geographic region) could have contributed milk to the affected silos. 

On January 17, regulatory officials collected on-farm bulk milk samples from suspected dairy farms and submitted them to the Washington Animal Disease Diagnostic Laboratory (WADDL), a member of the National Animal Health Laboratory Network (NAHLN). 

HPAI was confirmed via PCR at NVSL on Friday, January 24, in samples from two of those dairies. 

NVSL completed whole genome sequencing on January 31 and identified HPAI H5N1, clade 2.3.4.4b, genotype D1.1 in samples from four different bulk tanks from one herd. 

A second herd also showed a partial sequence consistent with D1.1. 

Clinical signs were not observed in the cattle prior to the detection, but have been reported since, and the affected dairy producers reported large wild bird die-offs near the dairies. 

While genotype D1.1 has been the dominant strain circulating in migratory wild birds across all four North American flyways during the winter of 2024-2025, these Nevada cases represent the f irst detection of a genotype other than B3.13 in U.S. dairy cattle and the second known spillover from wild birds into lactating dairy cattle. 

Virus Epidemiology and Origin 

Since late 2021, six separate introductions of Eurasian HPAI H5N1 clade 2.3.4.4b have been documented into the migratory wild birds in the North American flyways (genotypes A1 through A6). 

Genotype D1.1 is a reassortant of A3. Genotype A3 first appeared in the Pacific flyway in April of 2022 with detections only in the Pacific flyway until the fall of 2024. 

Since this fall, genotype A3 has been sporadically reported in migratory wild birds across all four flyways through wild bird surveillance, making up 3.3% of the overall detections to date. 

Genotype D1.1 retains four genes from the original A3 genotype; hemagglutinin (HA), polymerase basic 1 (PB1), matrix (M) and nonstructural (NS), with other genes originating from other North American lineage viruses found in migratory wild birds. 

This genotype was first detected in September 2024 and has quickly expanded to all North American flyways. 

D1.1 is the current predominant genotype in migratory wild birds, making up 6.07% of the total detections since 2022 despite f irst occurring late 2024. 

The D1.1 viruses identified in dairy cattle in Nevada were found to be closely related to other D1.1 viruses recently detected in migratory wild birds across multiple North American Flyways. 

Analysis of the hemagglutinin gene of the Nevada dairy cattle viruses did not identify changes predicted to impact infectivity or adaptation to mammalian hosts. 

However, a change of PB2 D701N commonly associated with mammalian adaptation of HPAI virus was identified in viruses sequenced from four separate dairy cattle. 

To date, this change has not been observed in D1.1 viruses found in wild birds or poultry and is not found in B3.13 genotype viruses detected in dairy cattle. 

PB2 D701N has previously been associated with mammalian adaptation because it improves RNA polymerase activity and replication efficiency in mammalian cells and has the potential to impact pathogenesis in infected mammals (2,3,4,5,6). 

The change has previously been identified in human cases of HPAI H5 but with no evidence of onward transmission among humans (7,8). 

No other changes associated with mammalian adaptation were identified in the sequences. 

Of note, these D1.1 viruses sequenced from dairy cattle do not contain the PB2 631L marker that appeared to be fixed in dairy cattle B3.13 sequences. 

Following the existing public sharing process, NVSL immediately provided the D1.1 sequence information the Centers for Disease Control and Prevention and will post sequence files to the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) within 7 days of analysis, adding metadata as sequences are interpreted and quality checked in light of epidemiological information.   

Summary 

This detection indicates that this HPAI virus, genotype D1.1, is the second spillover event from migratory wild birds to dairy cattle following the B3.13 event in late 2023/early 2024. 

Investigations are ongoing to fully characterize this event. The Nevada Department of Agriculture acted quickly, by first rapidly enrolling in the NMTS to initiate active surveillance, and then to identify and quarantine the affected dairies before cattle movements could further transmit this virus beyond the local area. 

This is the first instance where sampling of milk at processing plants rather than individually or directly on farm has detected a high consequence disease, demonstrating silo monitoring as an efficient method to monitor HPAI in the National dairy herd.  

1. Nguyen T, Hutter C, Markin A, Thomas M, Lantz K, Killian M, Janzen GM, Vijendran S, Wagle S, Inderski B, Magstadt DR, Li G, Diel DG, Frye EA, Dimitrov SM, Swinford A, Thompson AC, Snevik KR, Suarez DL, Spackman E, Lakin S, Ahola SC, Johnson SR, Baker A, Robbe-Austerman S, Torchetti M, Anderson TK. 2024. Emergence and interstate spread of highly pathogenic avian influenza A(H5N1) in dairy cattle. bioRxiv 2024.05.01.591751; doi: https://doi.org/10.1101/2024.05.01.591751 

2. Li Z, Chen H, Jiao P, Deng G, Tian G, Li Y, Hoffmann E, Webster RG, Matsuoka Y, Yu K. 2005. Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. The Journal of Virology 79:12058-12064. 

3. Gabriel G, Abram M, Keiner B, Wagner R, Klenk HD, Stech J. 2007. Differential polymerase activity in avian and mammalian cells determines host range of influenza virus. J Virol 81:9601-4. 

4. Steel J, Lowen AC, Mubareka S, Palese P. 2009. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog 5:e1000252. 

5. Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, Li Z, Guan Y, Tian G, Li Y, Shi J, Liu L, Zeng X, Bu Z, Xia X, Kawaoka Y, Chen H. 2009. Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. PLoSPathog 5:e1000709. 

6. Zhou B, Pearce MB, Li Y, Wang J, Mason RJ, Tumpey TM, Wentworth DE. 2013. Asparagine substitution at PB2 residue 701 enhances the replication, pathogenicity, and transmission of the 2009 pandemic H1N1 influenza A virus. PLoS ONE 8:e67616. 

7. Le QM, Ito M, Muramoto Y, Hoang PV, Vuong CD, Sakai-Tagawa Y, Kiso M, Ozawa M, Takano R, Kawaoka Y. 2010. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam. J Gen Virol 91:2485-90.  

8. Zhu W, Li X, Dong J, Bo H, Liu J, Yang J, Zhang Y, Wei H, Huang W, Zhao X, Chen T, Yang J, Li Z, Zeng X, Li C, Tang J, Xin L, Gao R, Liu L, Tan M, Shu Y, Yang L, Wang D. 2022. Epidemiologic, Clinical, and Genetic Characteristics of Human Infections with Influenza A(H5N6) Viruses, China. Emerg Infect Dis 28:1332-1344. 

Source: US Department of Health, https://www.aphis.usda.gov/sites/default/files/dairy-cattle-hpai-tech-brief.pdf

_____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater {Jan. 7 '25)

 {Excerpt}

Time Period: January 26 - February 01, 2025

-- H5 Detection: 17 sites (4.9%)

-- No Detection: 331 sites (95.1%)

-- No samples in last week: 51 sites

___

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html

_____

#USA, One #human infection with #H1N2 #variant #influenza virus has been reported by #Iowa

{Excerpt}

Novel Influenza A Virus Infections

One human infection with influenza A(H1N2) variant (A(H1N2)v) virus was reported by the Iowa Department of Health and Human Services.

The patient is ≥18 years of age and sought health care during the week ending January 18, 2025 (Week 3), was hospitalized, and has recovered from their illness. 

An investigation by state public health officials did not identify direct or indirect swine contact by the patent. 

No illness was identified among the patient's close contacts. 

No human-to-human transmission has been identified associated with this case.

This is the first human infection with a variant influenza virus reported during the 2024-2025 season in the United States.

When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. 

Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. 

It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person. 

Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

No new human infections with A(H5) were reported to CDC this week. An ongoing outbreak of H5N1 continues in domestic dairy cows and poultry, and monitoring for additional human cases is ongoing.

The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/position_statements_files_2023/24-ID-09_Novel_Influenza_A.pdf

An up-to-date human A(H5) case summary during the outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html

Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevention/hpai-interim-recommendations.html.

The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/animal-disease-information/avian/avian-influenza/2022-hpai.

(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2025-week-05.html

_____

#USA, After #Birdflu Detected in Local #Cat, County #Health Officials Say #Pet Owners Should Contact Veterinarian When Their Pets are Sick

Redwood City — State veterinary and health officials have confirmed a case of H5N1 (bird flu) in a domestic stray cat in San Mateo County. 

The infection, which is not related to the recent instance of bird flu in a backyard flock, was found in a stray cat in Half Moon Bay that had been taken in by a family. 

When it showed symptoms, they took it to Peninsula Humane Society, whose veterinarians examined it and requested testing. Lab results confirmed H5N1. 

It is not known how the cat was infected and it was euthanized due to its condition.

Cats may be exposed to bird flu by consuming infected bird, being in environments contaminated with the virus and consuming unpasteurized milk from infected cows or raw food. Inside domestic animals, such as cats and dogs, that go outside are also at risk of infection.​​​​​​​

According to the Centers for Disease Control and Prevention, the risk of cats spreading H5N1 to people is extremely low, though it is possible for cats to spread some strains of bird flu to people.

While there are no human cases of H5N1 related to this case, this detection in a cat highlights the importance of being proactive about preventing the spread of the virus.

Residents whose pets show signs of illness should contact their veterinarian.

Pets infected with H5N1 may experience a loss of appetite, lethargy and fever, along with neurologic signs, including circling, tremors, seizures or blindness. The illness may quickly progress to:

-- Severe depression

-- Discharge from eyes or nose

-- Other respiratory signs, such as rapid shallow breathing, difficulty breathing and sneezing or coughing

-- Pets with severe illness may die.

If a pet is showing signs of illness consistent with bird flu and has been exposed to infected (sick or dead) wild birds or poultry, residents should contact a veterinarian and monitor their own health for signs of fever or infection.

“We all want to make sure our companion animals are healthy and safe from disease,” said Lori Morton-Feazell, San Mateo County’s chief of Animal Control and Licensing. “If your pet is sick, your veterinarian can determine whether it should be tested for bird flu or any other virus or disease.”

(...)

Source: County of San Mateo, https://www.smcgov.org/ceo/news/after-bird-flu-detected-local-cat-county-health-officials-say-pet-owners-should-contact

_____

Highly Pathogenic Avian #Influenza Virus #H5N1 in Double-crested #Cormorants (Nannopterum auritum) of the #Chesapeake Bay, #USA

Abstract

Double-crested Cormorants (Nannopterum auritum) have historically exhibited low levels of infection and antibodies to avian influenza virus (AIV). The recent global expansion of clade 2.3.4.4b A/goose/Guangdong/1/1996 highly pathogenic (HP) avian influenza virus H5N1 (HPAI H5N1) has resulted in large-scale mortalities across diverse waterbird taxa including cormorants. We sampled 32 and 29 Double-crested Cormorants breeding in the Chesapeake Bay, US, during the summers of 2023 and 2024, respectively, to assess HPAI H5N1 infection and AIV antibodies. Although no mortality was observed in the area, one bird sampled in 2023 was infected with HPAI H5N1. Additionally, 21/31 individuals in 2023 and 10/25 individuals in 2024 for which sera were collected had AIV antibodies. Based on additional testing using hemagglutination inhibition, virus neutralization, and an enzyme-linked lectin assay, 94 and 100% (2023 and 2024, respectively) of the seropositive birds tested positive for antibodies to both H5 and N1, suggesting previous infection with HPAI H5N1. These results are consistent with survival and limited clinical effects related to HPAI H5N1 infections. Furthermore, these results suggest that population immunity to HPAI H5N1 within the Chesapeake Bay might reduce future infections and potential population impacts should HP H5N1 remain on the landscape, though immunity may be waning across time. Because results are based on a single population, additional testing for both infection and antibodies as well as continued monitoring could enhance understanding of antibody persistence.

Source: US National Library of Medicine, https://pubmed.ncbi.nlm.nih.gov/39911059/

____